Future Treatment Options in EGFR-Mutant NSCLC

EP: 1.Frontline Treatment Options in Metastatic EGFR-Mutated NSCLC

EP: 2.EGFR-Mutated NSCLC Disease Risk Stratification

EP: 3.Approaches to Patient Shared Decision-Making in EGFR-Mutated NSCLC

EP: 4.Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC

EP: 5.Expert Thoughts on Continuing Osimertinib Therapy Beyond First Disease Progression in EGFR-Mutant NSCLC

EP: 6.Treatment Sequencing in the Second Line and Beyond in EGFR-Mutant NSCLC

EP: 7.Amivantamab Toxicity Mitigation Strategies in the Treatment of EGFR-Mutant NSCLC

Now Viewing

EP: 8.Future Treatment Options in EGFR-Mutant NSCLC

Video content above is prompted by the following:

• There are several medications in the late stages of development, including the HER3-targeted ADC, patritumab, the TROP2 datopotamab, and the bispecific antibody ivonescimab, which targets both PD-1 and VEGF. How do their toxicity profiles differ from existing therapies, and do you anticipate them being used earlier in therapy?
• Recently approved treatment options in EGFR-mutated NSCLC have modestly improved progression-free survival but are associated with high toxicity rates. As new treatments continue to be introduced, how do you weigh the potential increased efficacy against the risk of increased toxicity?